Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations.

11 Jan 2013

Patients at high-risk for recurrent C. difficile with unnecessary antibiotic use

The impact of antibiotic misuse has far-reaching consequences in healthcare, including reduced efficacy of the drugs, increased prevalence of drug-resistant organisms, and increased risk of deadly infections. A new study featured in the February issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America, found that many patients with Clostridium difficile infection (C. difficile) are prescribed unnecessary antibiotics, increasing their risk of recurrence of the deadly infection.

10 Jan 2013

Minor mutations can lead to big improvements in antibiotic resistance

Rice University scientists have found that mutations of small effect can turn out to be game changers in the bacterial fight against antibiotic drugs.

10 Jan 2013

Concern regarding cefixime failure rate in gonorrhea patients

Results from a Canadian study add to those of prior studies suggesting that resistance of Neisseria gonorrhoeae to the cephalosporin antibiotic cefixime is increasing worldwide.

9 Jan 2013

Links between rodents' environment, climate and leptospirosis infection

Leptospirosis is a water-related bacterial disease with a high incidence in Southeast Asia. People usually become infected through exposure to water contaminated by the urine of infected animals, mainly rats and mice. In the framework of the CERoPath program, IRD researchers and their partners have revealed the relationship between rodents' environment and infection by leptospirosis bacteria.

9 Jan 2013

New compound restores health of mice with MRSA infection

Researchers have discovered a new compound that restores the health of mice infected with methicillin-resistant Staphylococcus aureus (MRSA), an otherwise dangerous bacterial infection. The new compound targets an enzyme not found in human cells but which is essential to bacterial survival.

8 Jan 2013

Complications of suppurative otitis media characterized

Researchers emphasize the importance of an early and accurate diagnosis of chronic suppurative otitis media followed by surgical therapy to prevent complications.

7 Jan 2013

ParoChip can allow dentists to quickly detect and analyze periodontitis pathogens

Bleeding gums during tooth brushing or when biting into an apple could be an indication of periodontitis, an inflammatory disease of the tissues that surround and support the teeth. Bacterial plaque attacks the bone, meaning teeth can loosen over time and in the worst case even fall out, as they are left without a solid foundation to hold them in place.

4 Jan 2013

Researchers uncover new way that some bacteria survive when under siege by antibiotics

Researchers have uncovered a new way that some bacteria survive when under siege by antibiotics.

4 Jan 2013

Optofluidics allow for new understanding of resistance to antibiotics

It's often difficult to completely eliminate a bacterial infection with antibiotics; part of the population usually manages to survive. We've known about this phenomenon for quite some time, dating back nearly to the discovery of penicillin. For more than 50 years, scientists have believed that the resistant bacteria were individuals that had stopped growing and dividing.

4 Jan 2013

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

3 Jan 2013

Novel implant for craniofacial reconstruction has mixed results

A single-stage, surface-mounted implant designed using the principles of the intraosseous transcutaneous amputation prosthesis is an effective bone anchor for an external prosthesis but may not produce good cosmetic outcomes in complex craniofacial reconstruction, researchers say.

3 Jan 2013

Antibiotics do not help lower-respiratory tract infections

The antibiotic amoxicillin fares no better at reducing symptoms in patients with lower-respiratory tract infections than a placebo drug, indicate data from a dozen European countries.

28 Dec 2012

Factors influencing anal sphincter injury risk ‘modifiable’

Researchers have identified several modifiable risk factors significantly associated with wound complications after obstetric anal sphincter injuries.

28 Dec 2012

Continuous vancomycin optimizes neonate therapy

Researchers recommend that a patient-tailored dosing regimen is used routinely in neonates for continuous infusion therapy of the antibiotic, vancomycin.

24 Dec 2012

Pergamum’s DPK-060 Phase II trial on acute external otitis meets primary end-point

Pergamum AB announced today that the primary end-point was met in the randomized Phase II trial of DPK-060 for treatment of acute external otitis.

21 Dec 2012

Ebselen effectively inhibits thioredoxin reductase system in H. pylori, M. tuberculosis

A drug currently being used to treat ischemic strokes may prove to be a significant advance in the treatment of tuberculosis and ulcers. In a new research report appearing online in The FASEB Journal, a compound called ebselen effectively inhibits the thioredoxin reductase system in a wide variety of bacteria, including Helicobacter pylori which causes gastric ulcers and Mycobacterium tuberculosis which causes tuberculosis.

21 Dec 2012

Antibiotic amoxicillin ineffective for treating cough according to European trial

The antibiotic amoxicillin, that doctors typically prescribe for common lower respiratory tract infections (LRTI) such as cough and bronchitis, is no more effective at relieving symptoms than the use of no medication, even in older patients. The findings from the largest randomised placebo controlled trial of antibiotics for acute uncomplicated LRTI to date are published Online First in The Lancet Infectious Diseases.

20 Dec 2012

US FDA approves raxibacumab for treating inhalational anthrax

The US Food and Drug Administration have approved the monoclonal antibody raxibacumab for treatment of inhalational anthrax, caused by breathing in spores of Bacillus anthracis.

19 Dec 2012

Probiotic supplements can benefit body during and after antibiotic use

Recent data suggests that the average American is bombarded with up to 5,000 varying media messages on a daily basis, which can make it tricky to discern fact from fiction. When it comes to your health, there should be absolutely no doubt that the products you select are effectively working to produce the desired results. This is especially true when it comes to the use of probiotics with antibiotics, because some forms are less effective when combined with antibiotics.

19 Dec 2012